Literature DB >> 20944799

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

J Curtis Nickel1, Carlos E Méndez-Probst, Thomas F Whelan, Ryan F Paterson, Hassan Razvi.   

Abstract

Entities:  

Year:  2010        PMID： 20944799      PMCID： PMC2950766          DOI： 10.5489/cuaj.10124

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  70 in total

1.  A randomized study comparing high-energy TUMT to TURP: quality-of-life results.

Authors:  E A Francisca; F C d'Ancona; J C Hendriks; L A Kiemeney; F M Debruyne; J J de La Rosette
Journal:  Eur Urol       Date:  2000-11       Impact factor: 20.096

2.  EAU Guidelines on benign prostatic hyperplasia (BPH).

Authors:  J J de la Rosette; G Alivizatos; S Madersbacher; M Perachino; D Thomas; F Desgrandchamps; M de Wildt
Journal:  Eur Urol       Date:  2001-09       Impact factor: 20.096

3.  Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia.

Authors:  S Madersbacher; G Schatzl; B Djavan; T Stulnig; M Marberger
Journal:  Eur Urol       Date:  2000-06       Impact factor: 20.096

4.  Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options.

Authors:  G Schatzl; S Madersbacher; B Djavan; T Lang; M Marberger
Journal:  Eur Urol       Date:  2000-06       Impact factor: 20.096

5.  Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer. Canadian Prostate Health Council.

Authors:  E W Ramsey; M Elhilali; S L Goldenberg; C J Nickel; R Norman; J P Perreault; B Piercy; J Trachtenberg
Journal:  J Urol       Date:  2000-02       Impact factor: 7.450

Review 6.  The progression of benign prostatic hyperplasia: examining the evidence and determining the risk.

Authors:  J B Anderson; C G Roehrborn; J A Schalken; M Emberton
Journal:  Eur Urol       Date:  2001-04       Impact factor: 20.096

7.  One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.

Authors:  B Lukacs; J C Grange; D Comet
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

8.  The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate.

Authors:  R G Hindley; A H Mostafid; R D Brierly; N W Harrison; P J Thomas; M S Fletcher
Journal:  BJU Int       Date:  2001-08       Impact factor: 5.588

Review 9.  Alpha adrenoceptor antagonists in the year 2000: is there anything new?

Authors:  C R Chapple
Journal:  Curr Opin Urol       Date:  2001-01       Impact factor: 2.309

10.  Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Q Yang; T J Peters; J L Donovan; T J Wilt; P Abrams
Journal:  J Urol       Date:  2001-05       Impact factor: 7.450
View more
  36 in total

1.  TURP in the new century: an analytical reappraisal in light of lasers.

Authors:  Assaad El-Hakim
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

2.  Let's not forget about TUIP: A highly underutilized, minimally-invasive and durable technique for men with <30 g prostates.

Authors:  Pierre-Alain Hueber; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 3.  A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms.

Authors:  Michael Erlano Chua; Jonathan Mendoza; Manuel See; Ednalyn Esmena; Dean Aguila; Jan Michael Silangcruz; Buenaventura Jose Reyes; Saturnino Luna; Marcelino Morales
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

4.  Picking your prostates.

Authors:  Blayne Welk
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

5.  Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?

Authors:  Li Tao Zhang; Jong Kwan Park
Journal:  World J Nephrol       Date:  2015-02-06

6.  Canadian trend in surgical management of benign prostatic hyperplasia and laser therapy from 2007-2008 to 2011-2012.

Authors:  Pierre-Alain Hueber; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

7.  Cost analysis of fixed-dose combination of dutasteride and tamsulosin compared with concomitant dutasteride and tamsulosin monotherapy in patients with benign prostatic hyperplasia in Canada.

Authors:  Amyn Sayani; Afisi Ismaila; Anna Walker; John Posnett; Bruno Laroche; J Curtis Nickel; Zhen Su
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

8.  The International Prostate Symptom Score (IPSS) Is an Inadequate Tool to Screen for Urethral Stricture Recurrence After Anterior Urethroplasty.

Authors:  Christopher A Tam; Sean P Elliott; Bryan B Voelzke; Jeremy B Myers; Alex J Vanni; Benjamin N Breyer; Thomas G Smith; Christopher D McClung; Bradley A Erickson
Journal:  Urology       Date:  2016-04-21       Impact factor: 2.649

9.  Guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers.

Authors:  Sheila-Mae Young; Praveen Bansal; Emily T Vella; Antonio Finelli; Cheryl Levitt; Andrew Loblaw
Journal:  Can Fam Physician       Date:  2015-01       Impact factor: 3.275

10.  Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.

Authors:  J Curtis Nickel; Lorne Aaron; Jack Barkin; Dean Elterman; Mahmoud Nachabé; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2018-10       Impact factor: 1.862
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.